Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan Followed by Pyrotinib + Fulvestrant + Dalpiciclib in HR+/HER2+ Advanced Breast Cancer
NCT07892274Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
A Phase 3 trial of pyrotinib, fulvestrant, dalpiciclib in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
pyrotinibfulvestrantdalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07892274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07892274.